

## Datasheet: STAR9B

<b>Description:</b>	RABBIT F(ab') <sub>2</sub> ANTI MOUSE IgG:FITC
<b>Specificity:</b>	IgG
<b>Format:</b>	FITC
<b>Product Type:</b>	Polyclonal Antibody
<b>Isotype:</b>	Polyclonal IgG
<b>Quantity:</b>	1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/25 - 1/100

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Mouse		
<b>Species Cross Reactivity</b>	Reacts with: Rat <b>N.B.</b> Antibody reactivity and working conditions may vary between species.		
<b>Product Form</b>	F(ab') <sub>2</sub> fragment of IgG conjugated to Fluorescein Isothiocyanate Isomer I (FITC) - liquid		
<b>Max Ex/Em</b>	<b>Fluorophore</b>	<b>Excitation Max (nm)</b>	<b>Emission Max (nm)</b>
	FITC	490	525

**Antiserum Preparation** Antisera to Mouse IgG were raised by repeated immunisation of rabbits with highly purified antigen. Purified IgG was prepared from whole serum by affinity chromatography. F(ab')<sub>2</sub> fragments were prepared by pepsin digestion of the IgG followed by a gel filtration step to remove the remaining intact IgG or Fc fragments.

<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide
<b>Approx. Protein Concentrations</b>	F(ab') <sub>2</sub> concentration 1.0 mg/ml
<b>Immunogen</b>	Purified mouse IgG.

**External Database  
Links**

**UniProt:**

<a href="#">P01869</a>	<a href="#">Related reagents</a>
<a href="#">P01865</a>	<a href="#">Related reagents</a>
<a href="#">P03987</a>	<a href="#">Related reagents</a>
<a href="#">P01864</a>	<a href="#">Related reagents</a>
<a href="#">P01867</a>	<a href="#">Related reagents</a>
<a href="#">P01868</a>	<a href="#">Related reagents</a>
<a href="#">P01863</a>	<a href="#">Related reagents</a>

**Entrez Gene:**

<a href="#">16017</a>	Ighg1	<a href="#">Related reagents</a>
<a href="#">380793</a>	Igh-1a	<a href="#">Related reagents</a>
<a href="#">16016</a>	Ighg2b	<a href="#">Related reagents</a>
<a href="#">16017</a>	Ighg1	<a href="#">Related reagents</a>
<a href="#">380793</a>	Igh-1a	<a href="#">Related reagents</a>
<a href="#">380795</a>	AI324046	<a href="#">Related reagents</a>
<a href="#">380793</a>	Igh-1a	<a href="#">Related reagents</a>

---

**Synonyms**

Igh-4

---

**Specificity**

**FITC conjugated Rabbit F(ab')<sub>2</sub> anti Mouse IgG antibody** recognizes all subclasses of mouse IgG.

Some cross reactivity with mouse IgM and IgA is expected, as is cross reactivity with rat IgG. Cross reactivity with human serum proteins has been minimised by solid phase adsorption.

---

**Flow Cytometry**

Use 50ul of the suggested working dilution to label 10<sup>6</sup> cells in 100ul.

---

**References**

1. O-charoenrat, P. *et al.* (2000) Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. [Cancer Res. 60 \(4\): 1121-8.](#)
2. Lamote, I. *et al.* (2004) Influence of 17beta-estradiol, progesterone, and dexamethasone on diapedesis and viability of bovine blood polymorphonuclear leukocytes. [J Dairy Sci. 87 \(10\): 3340-9.](#)
3. Dalli, J. *et al.* (2008) Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. [Blood. 112 \(6\): 2512-9.](#)
4. Fleming, E.H. *et al.* (2006) Respiratory syncytial virus F envelope protein associates with lipid rafts without a requirement for other virus proteins. [J Virol. 80: 12160-70.](#)
5. Peretti, M. *et al.* (2001) Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP. [Mol Cell Biol. 21: 5699-709.](#)
6. Krawczyk, M. *et al.* (2005) New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study. [Mol Cell Biol. 25: 8607-18.](#)
7. Frenzel, R. *et al.* (2006) The human thyrotropin receptor is predominantly internalized by beta-arrestin 2. [Endocrinology. 147: 3114-22.](#)
8. Brancaleone, V. *et al.* (2011) Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. [J Immunol. 186: 4905-14.](#)
9. Wacławicek, M. *et al.* (2009) Analysis of the early response to TSST-1 reveals Vbeta-unrestricted extravasation, compartmentalization of the response, and unresponsiveness but not anergy to

TSST-1. [J Leukoc Biol. 85: 44-54.](#)

10. Maderna, P. *et al.* (2010) FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. [FASEB J. 24: 4240-9.](#)

11. Ioannou, N. *et al.* (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. [Br J Cancer. 105: 1554-62.](#)

12. Renshaw, D. *et al.* (2010) Downstream gene activation of the receptor ALX by the agonist annexin A1. [PLoS One. 5. pii: e12771.](#)

13. Bena, S. *et al.* (2012) Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. [J Biol Chem. 287: 24690-7.](#)

14. Mehta, K. *et al.* (2016) Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells [Blood Cells Mol Dis. Jun 30 \[Epub ahead of print\]](#)

15. Puvanenthiran, S. *et al.* (2016) Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. [Int J Oncol. 49 \(5\): 1825-38.](#)

16. Ioannou, N. *et al.* (2013) Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. [BMC Cancer. 13: 41.](#)

---

**Storage**

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Shelf Life**

18 months from date of despatch.

---

**Health And Safety Information**

Material Safety Datasheet documentation #10040 available at:  
10040: <https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf>

---

**Regulatory**

For research purposes only

---

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

'M325390:180727'

**Printed on 18 Sep 2018**

---

© 2018 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)